Matches in SemOpenAlex for { <https://semopenalex.org/work/W1567117625> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W1567117625 endingPage "5" @default.
- W1567117625 startingPage "2180" @default.
- W1567117625 abstract "Synergy, when it can be convincingly established, is an effective strategy for the development of novel drug combinations. We have evaluated the interaction between 2'-deoxy-5-azacytidine (DAC) and 9-dimethylaminomethyl-10-hydroxycamptothecin (topotecan) based on our hypothesis that DAC, through DNA hypomethylation, might increase the transcription of topoisomerase I (topo I) leading to increased sensitivity to topotecan. Five human tumor cell lines, A375 melanoma, DX-3 melanoma, DMS4C non-small cell lung carcinoma, UP-1 unknown primary adenocarcinoma, SN12C renal carcinoma, and the murine CT-26 tumor cell line, were studied. Drug interactions were assessed using the multiple drug effect analysis of Chou and Talalay (Chors, T-C, and Talalay, P. Adv. Enzyme Regul., 22:27-54, 1984.). A synergistic interaction was documented in four human cell lines and the murine CT-26 line. An antagonistic interaction was observed with the SN12C cell line. The toxicology and efficacy of this combination were analyzed using CT-26 in BALB/c mice. Various treatment schedules were studied, including: single doses of each agent; single sequential combination treatments where DAC was administered followed by topotecan 24 h later; and multiple sequential treatments where DAC and topotecan were administered on days 1, 2, 8, and 9. Efficacy studies showed that the single sequential combination of DAC (50 mg/kg) and topotecan (10 mg/kg) resulted in tumor growth delay as compared to single doses of DAC (50 mg/kg) or topotecan (10 mg/kg). When the multiple sequential combination schedule was used, the antitumor effect was more pronounced. In that experiment 50% of the control animals had tumors of 20 mm by day 28. For animals receiving a single sequential treatment with DAC and topotecan, the median time until the mean tumor size reached 20 mm was 38 days, and for the group with multiple sequential combination treatments the time was 51 days. Studies of the mechanism of the interaction showed that the activity of topotecan versus each cell line correlated with the topo I activity in nuclear extracts However, there was no correlation between topo I levels and synergy and no reproducible increase in topo I activity following exposure to DAC. Thus, while the exact mechanism of the interaction remains unclear, DAC can be effectively combined with topotecan to enhance antitumor activity." @default.
- W1567117625 created "2016-06-24" @default.
- W1567117625 creator A5061866845 @default.
- W1567117625 creator A5087376683 @default.
- W1567117625 creator A5090623337 @default.
- W1567117625 date "1992-04-15" @default.
- W1567117625 modified "2023-09-23" @default.
- W1567117625 title "Synergistic cytotoxicity with 2'-deoxy-5-azacytidine and topotecan in vitro and in vivo." @default.
- W1567117625 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1373105" @default.
- W1567117625 hasPublicationYear "1992" @default.
- W1567117625 type Work @default.
- W1567117625 sameAs 1567117625 @default.
- W1567117625 citedByCount "21" @default.
- W1567117625 countsByYear W15671176252016 @default.
- W1567117625 countsByYear W15671176252017 @default.
- W1567117625 countsByYear W15671176252018 @default.
- W1567117625 countsByYear W15671176252020 @default.
- W1567117625 countsByYear W15671176252021 @default.
- W1567117625 countsByYear W15671176252022 @default.
- W1567117625 crossrefType "journal-article" @default.
- W1567117625 hasAuthorship W1567117625A5061866845 @default.
- W1567117625 hasAuthorship W1567117625A5087376683 @default.
- W1567117625 hasAuthorship W1567117625A5090623337 @default.
- W1567117625 hasConcept C109316439 @default.
- W1567117625 hasConcept C126322002 @default.
- W1567117625 hasConcept C147897179 @default.
- W1567117625 hasConcept C150903083 @default.
- W1567117625 hasConcept C185592680 @default.
- W1567117625 hasConcept C202751555 @default.
- W1567117625 hasConcept C207001950 @default.
- W1567117625 hasConcept C2776694085 @default.
- W1567117625 hasConcept C2777292972 @default.
- W1567117625 hasConcept C2777658100 @default.
- W1567117625 hasConcept C2778119113 @default.
- W1567117625 hasConcept C2778143360 @default.
- W1567117625 hasConcept C2779682216 @default.
- W1567117625 hasConcept C2781209748 @default.
- W1567117625 hasConcept C502942594 @default.
- W1567117625 hasConcept C54355233 @default.
- W1567117625 hasConcept C55493867 @default.
- W1567117625 hasConcept C71240020 @default.
- W1567117625 hasConcept C71924100 @default.
- W1567117625 hasConcept C81885089 @default.
- W1567117625 hasConcept C86803240 @default.
- W1567117625 hasConcept C98274493 @default.
- W1567117625 hasConceptScore W1567117625C109316439 @default.
- W1567117625 hasConceptScore W1567117625C126322002 @default.
- W1567117625 hasConceptScore W1567117625C147897179 @default.
- W1567117625 hasConceptScore W1567117625C150903083 @default.
- W1567117625 hasConceptScore W1567117625C185592680 @default.
- W1567117625 hasConceptScore W1567117625C202751555 @default.
- W1567117625 hasConceptScore W1567117625C207001950 @default.
- W1567117625 hasConceptScore W1567117625C2776694085 @default.
- W1567117625 hasConceptScore W1567117625C2777292972 @default.
- W1567117625 hasConceptScore W1567117625C2777658100 @default.
- W1567117625 hasConceptScore W1567117625C2778119113 @default.
- W1567117625 hasConceptScore W1567117625C2778143360 @default.
- W1567117625 hasConceptScore W1567117625C2779682216 @default.
- W1567117625 hasConceptScore W1567117625C2781209748 @default.
- W1567117625 hasConceptScore W1567117625C502942594 @default.
- W1567117625 hasConceptScore W1567117625C54355233 @default.
- W1567117625 hasConceptScore W1567117625C55493867 @default.
- W1567117625 hasConceptScore W1567117625C71240020 @default.
- W1567117625 hasConceptScore W1567117625C71924100 @default.
- W1567117625 hasConceptScore W1567117625C81885089 @default.
- W1567117625 hasConceptScore W1567117625C86803240 @default.
- W1567117625 hasConceptScore W1567117625C98274493 @default.
- W1567117625 hasIssue "8" @default.
- W1567117625 hasLocation W15671176251 @default.
- W1567117625 hasOpenAccess W1567117625 @default.
- W1567117625 hasPrimaryLocation W15671176251 @default.
- W1567117625 hasRelatedWork W1995556774 @default.
- W1567117625 hasRelatedWork W1996537678 @default.
- W1567117625 hasRelatedWork W2013317272 @default.
- W1567117625 hasRelatedWork W2054837357 @default.
- W1567117625 hasRelatedWork W2065428450 @default.
- W1567117625 hasRelatedWork W2158858339 @default.
- W1567117625 hasRelatedWork W2170830299 @default.
- W1567117625 hasRelatedWork W2427594931 @default.
- W1567117625 hasRelatedWork W2468416386 @default.
- W1567117625 hasRelatedWork W2501769632 @default.
- W1567117625 hasVolume "52" @default.
- W1567117625 isParatext "false" @default.
- W1567117625 isRetracted "false" @default.
- W1567117625 magId "1567117625" @default.
- W1567117625 workType "article" @default.